Synopsis of Key Gynecologic Oncology Trials
portes grátis
Synopsis of Key Gynecologic Oncology Trials
Renz, Malte; Diver, Elisabeth; Growdon, Whitfield; Dorigo, Oliver
Taylor & Francis Ltd
12/2022
160
Mole
Inglês
9781032135328
15 a 20 dias
312
Descrição não disponível.
Preface to the second edition
1. Uterine Malignancies. 1.1. Endometrial Carcinoma. 1.1.1. Studies addressing surgical treatment. 1.1.1.1. Lymph node assessment 1.1.2. Studies addressing adjuvant therapy. 1.1.2.1. Radiation. 1.1.2.2. Chemoradiation. 1.1.2.3. Chemotherapy. 1.1.3. Studies addressing treatment of recurrent endometrial carcinoma. 1.1.3.1. Hormonal therapy. 1.1.3.2. Chemotherapy. 1.1.3.3. Targeted therapy. 1.1.3.4. Immunotherapy. 1.2. Uterine Carcinosarcoma. 1.2.1. Studies addressing prognosticators. 1.2.2. Studies addressing adjuvant treatment. 1.2.3. Studies addressing treatment of advanced/ recurrent uterine carcinosarcoma. 1.3. Uterine Leiomyosarcoma. 1.3.1. Studies addressing adjuvant treatment of early stage uterine leiomyosarcoma. 1.3.2. Studies addressing treatment of advanced uterine leiomyosarcoma. 1.4. References.
2. Ovarian Malignancies. 2.1. Epithelial ovarian cancer (EOC). 2.1.1. Studies addressing upfront surgery. 2.1.2. Studies addressing adjuvant therapy. 2.1.3. Studies addressing intraperitoneal chemotherapy. 2.1.4. Studies addressing first line maintenance treatment. 2.1.5. Studies addressing neoadjuvant therapy. 2.1.6. Studies addressing prediction of debulking. 2.1.7. Studies addressing time point of treatment of recurrence. 2.1.8. Studies addressing treatment of recurrent ovarian cancer, platinum-sensitive. 2.1.8.1. Chemotherapy and targeted therapy. 2.1.8.2. Secondary debulking surgery. 2.1.9. Studies addressing treatment of recurrent ovarian cancer, platinum-resistant. 2.1.9.1. Chemotherapy and targeted therapy. 2.1.9.2. Immunotherapy. 2.2. Low grade serous ovarian cancer. 2.3. Mucinous epithelial ovarian cancer (mEOC). 2.4. Ovarian Germ Cell Tumors (GCT). 2.5. Ovarian Sex Cord-Stromal Tumors (SCT). 2.6. References.
3. Cervical Cancer. 3.1. Studies addressing surgical treatment. 3.2. Studies addressing adjuvant therapy. 3.3. Studies addressing primary chemoradiation therapy. 3.4. Studies addressing treatment of recurrent or metastatic cervical cancer. 3.4.1. Chemotherapy and targeted therapy. 3.4.2. Immunotherapy. 3.5. References.
4. Vulvar Cancer. 4.1. Studies addressing surgical treatment. 4.1.1. Groin lymph nodes. 4.2. Studies addressing advanced vulvar cancer. 4.2.1. Chemoradiation. 4.2.2. Immunotherapy. 4.3. References.
5. Gestational Trophoblastic Neoplasia (GTN). 5.1. Studies addressing surgical treatment. 5.2. Studies addressing chemotherapy in low-risk GTN. 5.3. Studies addressing (chemo)therapy in high-risk GTN. 5.4. References.
6. Glossary. Index.
1. Uterine Malignancies. 1.1. Endometrial Carcinoma. 1.1.1. Studies addressing surgical treatment. 1.1.1.1. Lymph node assessment 1.1.2. Studies addressing adjuvant therapy. 1.1.2.1. Radiation. 1.1.2.2. Chemoradiation. 1.1.2.3. Chemotherapy. 1.1.3. Studies addressing treatment of recurrent endometrial carcinoma. 1.1.3.1. Hormonal therapy. 1.1.3.2. Chemotherapy. 1.1.3.3. Targeted therapy. 1.1.3.4. Immunotherapy. 1.2. Uterine Carcinosarcoma. 1.2.1. Studies addressing prognosticators. 1.2.2. Studies addressing adjuvant treatment. 1.2.3. Studies addressing treatment of advanced/ recurrent uterine carcinosarcoma. 1.3. Uterine Leiomyosarcoma. 1.3.1. Studies addressing adjuvant treatment of early stage uterine leiomyosarcoma. 1.3.2. Studies addressing treatment of advanced uterine leiomyosarcoma. 1.4. References.
2. Ovarian Malignancies. 2.1. Epithelial ovarian cancer (EOC). 2.1.1. Studies addressing upfront surgery. 2.1.2. Studies addressing adjuvant therapy. 2.1.3. Studies addressing intraperitoneal chemotherapy. 2.1.4. Studies addressing first line maintenance treatment. 2.1.5. Studies addressing neoadjuvant therapy. 2.1.6. Studies addressing prediction of debulking. 2.1.7. Studies addressing time point of treatment of recurrence. 2.1.8. Studies addressing treatment of recurrent ovarian cancer, platinum-sensitive. 2.1.8.1. Chemotherapy and targeted therapy. 2.1.8.2. Secondary debulking surgery. 2.1.9. Studies addressing treatment of recurrent ovarian cancer, platinum-resistant. 2.1.9.1. Chemotherapy and targeted therapy. 2.1.9.2. Immunotherapy. 2.2. Low grade serous ovarian cancer. 2.3. Mucinous epithelial ovarian cancer (mEOC). 2.4. Ovarian Germ Cell Tumors (GCT). 2.5. Ovarian Sex Cord-Stromal Tumors (SCT). 2.6. References.
3. Cervical Cancer. 3.1. Studies addressing surgical treatment. 3.2. Studies addressing adjuvant therapy. 3.3. Studies addressing primary chemoradiation therapy. 3.4. Studies addressing treatment of recurrent or metastatic cervical cancer. 3.4.1. Chemotherapy and targeted therapy. 3.4.2. Immunotherapy. 3.5. References.
4. Vulvar Cancer. 4.1. Studies addressing surgical treatment. 4.1.1. Groin lymph nodes. 4.2. Studies addressing advanced vulvar cancer. 4.2.1. Chemoradiation. 4.2.2. Immunotherapy. 4.3. References.
5. Gestational Trophoblastic Neoplasia (GTN). 5.1. Studies addressing surgical treatment. 5.2. Studies addressing chemotherapy in low-risk GTN. 5.3. Studies addressing (chemo)therapy in high-risk GTN. 5.4. References.
6. Glossary. Index.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
evidence base for cancer treatment;gyn onc clinical trials;key cancer trials;cervical cancer;gestational trophoblastic neoplasia;gynecologic cancer treatment;ovarian malignancy;clinical trial;oncology revision;oncology primer;Median PFS;oncology boards primer;Carboplatin AUC;Median Dor;Vulvar Cancer;Stage Ii;Platinum Sensitive Recurrent Ovarian Cancer;LN Metastasis;PD L1 Expression;Endometrial Cancer;SLN Sampling;Low Grade Serous Ovarian Cancer;PSTT;PD L1 Positive Tumor;Prior Systemic Treatment;BRCA Mutation;Secondary Cytoreduction;Early Stage EOC;Ovarian Cancer;Dose Dense Paclitaxel;Olaparib Maintenance;Platinum Sensitive Ovarian Cancer;Recurrent Endometrial Cancer;Advanced EOC
Preface to the second edition
1. Uterine Malignancies. 1.1. Endometrial Carcinoma. 1.1.1. Studies addressing surgical treatment. 1.1.1.1. Lymph node assessment 1.1.2. Studies addressing adjuvant therapy. 1.1.2.1. Radiation. 1.1.2.2. Chemoradiation. 1.1.2.3. Chemotherapy. 1.1.3. Studies addressing treatment of recurrent endometrial carcinoma. 1.1.3.1. Hormonal therapy. 1.1.3.2. Chemotherapy. 1.1.3.3. Targeted therapy. 1.1.3.4. Immunotherapy. 1.2. Uterine Carcinosarcoma. 1.2.1. Studies addressing prognosticators. 1.2.2. Studies addressing adjuvant treatment. 1.2.3. Studies addressing treatment of advanced/ recurrent uterine carcinosarcoma. 1.3. Uterine Leiomyosarcoma. 1.3.1. Studies addressing adjuvant treatment of early stage uterine leiomyosarcoma. 1.3.2. Studies addressing treatment of advanced uterine leiomyosarcoma. 1.4. References.
2. Ovarian Malignancies. 2.1. Epithelial ovarian cancer (EOC). 2.1.1. Studies addressing upfront surgery. 2.1.2. Studies addressing adjuvant therapy. 2.1.3. Studies addressing intraperitoneal chemotherapy. 2.1.4. Studies addressing first line maintenance treatment. 2.1.5. Studies addressing neoadjuvant therapy. 2.1.6. Studies addressing prediction of debulking. 2.1.7. Studies addressing time point of treatment of recurrence. 2.1.8. Studies addressing treatment of recurrent ovarian cancer, platinum-sensitive. 2.1.8.1. Chemotherapy and targeted therapy. 2.1.8.2. Secondary debulking surgery. 2.1.9. Studies addressing treatment of recurrent ovarian cancer, platinum-resistant. 2.1.9.1. Chemotherapy and targeted therapy. 2.1.9.2. Immunotherapy. 2.2. Low grade serous ovarian cancer. 2.3. Mucinous epithelial ovarian cancer (mEOC). 2.4. Ovarian Germ Cell Tumors (GCT). 2.5. Ovarian Sex Cord-Stromal Tumors (SCT). 2.6. References.
3. Cervical Cancer. 3.1. Studies addressing surgical treatment. 3.2. Studies addressing adjuvant therapy. 3.3. Studies addressing primary chemoradiation therapy. 3.4. Studies addressing treatment of recurrent or metastatic cervical cancer. 3.4.1. Chemotherapy and targeted therapy. 3.4.2. Immunotherapy. 3.5. References.
4. Vulvar Cancer. 4.1. Studies addressing surgical treatment. 4.1.1. Groin lymph nodes. 4.2. Studies addressing advanced vulvar cancer. 4.2.1. Chemoradiation. 4.2.2. Immunotherapy. 4.3. References.
5. Gestational Trophoblastic Neoplasia (GTN). 5.1. Studies addressing surgical treatment. 5.2. Studies addressing chemotherapy in low-risk GTN. 5.3. Studies addressing (chemo)therapy in high-risk GTN. 5.4. References.
6. Glossary. Index.
1. Uterine Malignancies. 1.1. Endometrial Carcinoma. 1.1.1. Studies addressing surgical treatment. 1.1.1.1. Lymph node assessment 1.1.2. Studies addressing adjuvant therapy. 1.1.2.1. Radiation. 1.1.2.2. Chemoradiation. 1.1.2.3. Chemotherapy. 1.1.3. Studies addressing treatment of recurrent endometrial carcinoma. 1.1.3.1. Hormonal therapy. 1.1.3.2. Chemotherapy. 1.1.3.3. Targeted therapy. 1.1.3.4. Immunotherapy. 1.2. Uterine Carcinosarcoma. 1.2.1. Studies addressing prognosticators. 1.2.2. Studies addressing adjuvant treatment. 1.2.3. Studies addressing treatment of advanced/ recurrent uterine carcinosarcoma. 1.3. Uterine Leiomyosarcoma. 1.3.1. Studies addressing adjuvant treatment of early stage uterine leiomyosarcoma. 1.3.2. Studies addressing treatment of advanced uterine leiomyosarcoma. 1.4. References.
2. Ovarian Malignancies. 2.1. Epithelial ovarian cancer (EOC). 2.1.1. Studies addressing upfront surgery. 2.1.2. Studies addressing adjuvant therapy. 2.1.3. Studies addressing intraperitoneal chemotherapy. 2.1.4. Studies addressing first line maintenance treatment. 2.1.5. Studies addressing neoadjuvant therapy. 2.1.6. Studies addressing prediction of debulking. 2.1.7. Studies addressing time point of treatment of recurrence. 2.1.8. Studies addressing treatment of recurrent ovarian cancer, platinum-sensitive. 2.1.8.1. Chemotherapy and targeted therapy. 2.1.8.2. Secondary debulking surgery. 2.1.9. Studies addressing treatment of recurrent ovarian cancer, platinum-resistant. 2.1.9.1. Chemotherapy and targeted therapy. 2.1.9.2. Immunotherapy. 2.2. Low grade serous ovarian cancer. 2.3. Mucinous epithelial ovarian cancer (mEOC). 2.4. Ovarian Germ Cell Tumors (GCT). 2.5. Ovarian Sex Cord-Stromal Tumors (SCT). 2.6. References.
3. Cervical Cancer. 3.1. Studies addressing surgical treatment. 3.2. Studies addressing adjuvant therapy. 3.3. Studies addressing primary chemoradiation therapy. 3.4. Studies addressing treatment of recurrent or metastatic cervical cancer. 3.4.1. Chemotherapy and targeted therapy. 3.4.2. Immunotherapy. 3.5. References.
4. Vulvar Cancer. 4.1. Studies addressing surgical treatment. 4.1.1. Groin lymph nodes. 4.2. Studies addressing advanced vulvar cancer. 4.2.1. Chemoradiation. 4.2.2. Immunotherapy. 4.3. References.
5. Gestational Trophoblastic Neoplasia (GTN). 5.1. Studies addressing surgical treatment. 5.2. Studies addressing chemotherapy in low-risk GTN. 5.3. Studies addressing (chemo)therapy in high-risk GTN. 5.4. References.
6. Glossary. Index.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
evidence base for cancer treatment;gyn onc clinical trials;key cancer trials;cervical cancer;gestational trophoblastic neoplasia;gynecologic cancer treatment;ovarian malignancy;clinical trial;oncology revision;oncology primer;Median PFS;oncology boards primer;Carboplatin AUC;Median Dor;Vulvar Cancer;Stage Ii;Platinum Sensitive Recurrent Ovarian Cancer;LN Metastasis;PD L1 Expression;Endometrial Cancer;SLN Sampling;Low Grade Serous Ovarian Cancer;PSTT;PD L1 Positive Tumor;Prior Systemic Treatment;BRCA Mutation;Secondary Cytoreduction;Early Stage EOC;Ovarian Cancer;Dose Dense Paclitaxel;Olaparib Maintenance;Platinum Sensitive Ovarian Cancer;Recurrent Endometrial Cancer;Advanced EOC
